The company is already involved in clinical studies with its product in order to evaluate the relevance and usefulness of the gut microbiome in the field of medical therapies. In the future, the aim is for diagnoses and specific therapy plans to be based on the individual intestinal microbiome of patients.
Using standardised interfaces, laboratories and hospitals are offered a simple and inexpensive way to integrate the analysis platform developed by myBioma into their own applications.
“We are concentrating on tapping into the diverse, diagnostic potential of the gut microbiome. Our vision is to optimise existing medical treatments based on our analysis of intestinal bacteria. We aim to achieve this by application of the latest technologies, such as next-generation sequencing of bacterial genes, ”says Dr. Nikolaus Gasche, Co-founder of myBioma.